Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

Rhea-AI Summary

Organogenesis (Nasdaq: ORGO) will report fourth quarter and fiscal year 2025 financial results after market close on Thursday, February 26, 2026.

Management will host a conference call and live webcast at 5:00 p.m. ET on February 26 to discuss results and provide a corporate update; the webcast will be archived on the company website for about one year.

News Market Reaction – ORGO

+2.99%

1 alert

+2.99% News Effect

On the day this news was published, ORGO gained 2.99%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings date: February 26, 2026 Conference call time: 5:00 p.m. Eastern Time Webcast archive duration: approximately one year

3 metrics

Earnings date February 26, 2026 Scheduled Q4 and FY2025 results release after market close

Conference call time 5:00 p.m. Eastern Time Time for Q4 and FY2025 results conference call

Webcast archive duration approximately one year Length of time earnings webcast will remain available online

Market Reality Check

Price: $4.03 Vol: Volume 170,097 is 0.31x t...

low vol

$4.03 Last Close

Volume Volume 170,097 is 0.31x the 20-day average of 549,792, indicating muted trading ahead of the earnings date. low

Technical Shares last traded at $3.84, below the 200-day MA of $4.35 and 45.74% under the 52-week high of $7.0771.

Peers on Argus

Pre-news, ORGO was up 2.99%. Peers were mixed: SIGA (+0.15%), AQST (+0.52%), ESP...

1 Up

Pre-news, ORGO was up 2.99%. Peers were mixed: SIGA (+0.15%), AQST (+0.52%), ESPR (+0.56%), AKBA (flat in sector list but later flagged up 2.54% in momentum scan without news), and EOLS (-0.91%). This pattern points to stock-specific factors rather than a sector-wide move.

Common Catalyst Another peer, AKBA, also announced an earnings date, suggesting companies in the space are entering their reporting window, but only one peer had related news today.

Historical Context

5 past events · Latest: Jan 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Executive promotions	Neutral	-4.8%	Avista Healthcare Partners promoted investment team members tied to ORGO’s board.
Dec 23	BLA initiation	Positive	+2.1%	Initiated rolling BLA submission to FDA for ReNu in knee osteoarthritis.
Dec 15	FDA meeting update	Positive	+0.2%	Reported successful FDA Type-B meeting and plan to begin rolling BLA for ReNu.
Nov 06	Q3 2025 earnings	Positive	-2.0%	Posted record Q3 revenue, higher earnings, and raised FY2025 guidance.
Nov 03	CMS payment reform	Positive	-5.9%	Highlighted CMS payment reform seen as supportive for skin substitute products.

Pattern Detected

Positive fundamental or regulatory news has produced mixed reactions: several favorable FDA/CMS and earnings updates saw both modest gains and notable selloffs, indicating inconsistent alignment between news tone and price moves.

Recent Company History

Over the last few months, ORGO has reported several significant milestones. On Nov 3, 2025, it highlighted CMS payment reform viewed as supportive for PMA technologies, yet shares fell 5.88%. On Nov 6, 2025, record Q3 2025 revenue and raised FY2025 guidance coincided with a 2.02% decline. Later, a successful FDA meeting and subsequent rolling BLA for ReNu in December 2025 brought modest gains of 0.21% and 2.09%. A January 2026 promotion-focused article for an investment partner saw shares down 4.85%. Today’s earnings-date announcement fits into this backdrop of meaningful catalysts but uneven price responses.

Market Pulse Summary

This announcement sets February 26, 2026 as the date for ORGO’s Q4 and FY2025 results, with a confer...

Analysis

This announcement sets February 26, 2026 as the date for ORGO’s Q4 and FY2025 results, with a conference call at 5:00 p.m. Eastern Time. It follows a period of key developments, including CMS payment reform, record Q3 2025 results, and advancing the ReNu BLA. With the stock at $3.84, below its $4.35 200-day MA and 45.74% under the $7.0771 52-week high, investors may focus on how upcoming financials and pipeline updates compare with these prior catalysts.

AI-generated analysis. Not financial advice.

CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2025 financial results will be reported after the market closes on Thursday, February 26th.

Management will host a conference call at 5:00 p.m. Eastern Time on February 26th to discuss the results of the quarter and the fiscal year, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.

About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.

Investor Inquiries:
ICR Healthcare
Mike Piccinino, CFA
OrganoIR@icrinc.com

Press and Media Inquiries:
Organogenesis
communications@organo.com

FAQ

When will Organogenesis (ORGO) release Q4 and FY2025 results?

Organogenesis will release Q4 and FY2025 results after market close on February 26, 2026. According to the company, results will be published after the market closes with a management conference call and webcast scheduled later that day.

What time is the ORGO conference call and webcast on February 26, 2026?

The ORGO conference call and webcast is scheduled for 5:00 p.m. Eastern Time on February 26, 2026. According to the company, management will discuss the quarter, provide a corporate update, and hold a Q&A session during the call.

How can investors access the Organogenesis (ORGO) live webcast on February 26?

Investors can access the live webcast via the company’s investor website at investors.organogenesis.com. According to the company, links to the live webcast and teleconference will be available for participants and the webcast will be archived afterward.

Will Organogenesis (ORGO) archive the February 26, 2026 webcast and for how long?

Yes, the company will archive the February 26 webcast on its investor website for approximately one year. According to the company, the archived webcast will remain available on the website for roughly twelve months following the event.

What will management cover during the ORGO Feb. 26, 2026 call?

Management will discuss fourth quarter and full fiscal year 2025 results and provide a corporate update with Q&A. According to the company, the call and webcast are intended to review financial results and answer investor questions about recent developments.